China's top disease control official has said the country is formally considering mixing COVID-19 vaccines as a way of further boosting vaccine efficacy.

Available data shows&nbsp;Chinese&nbsp;vaccines lag behind others including Pfizer and Moderna in terms of efficacy, but require less stringent temperature controls during storage.

Giving people doses of different vaccines is one way to improve vaccines that "don't have very high rates of protection", Gao Fu, the director of the&nbsp;Chinese&nbsp;Centers for Disease Control and Prevention, said on Saturday, without specifying whether he was referring to foreign or domestic vaccines

"Inoculation using vaccines of different technical lines is being considered," Gao told a conference in the&nbsp;Chinese&nbsp;city of Chengdu.

Gao said that taking steps to "optimise" the vaccine process including changing the number of doses and the length of time between doses was a "definite" solution to efficacy issues.

Two injections of a vaccine developed by China's Sinovac Biotech, when given shorter than three weeks apart, was 49.1 per cent&nbsp;effective based on data from a Phase III trial in Brazil, below the 50 per cent&nbsp;threshold set by World Health Organization, according to a paper published by Brazilian researchers on Sunday ahead of peer review.

But data from a small subgroup showed that the efficacy rate increased to 62.3 per cent&nbsp;when the doses were given at intervals of three weeks and longer. The overall efficacy rate for the vaccine was slightly above 50 per cent&nbsp;in the trial.

China has developed four domestic vaccines approved for public use and a fifth for smaller-scale emergency use. An official said on Saturday that the country will likely produce 3 billion doses by the end of the year.

No detailed efficacy data has been released on vaccines made by China's Sinopharm. It has said two vaccines developed by its units are 79.4 per cent&nbsp;and 72.5 per cent&nbsp;effective respectively, based on interim results.

Both vaccine makers have presented data on their COVID-19 vaccines indicating levels of efficacy in line with those required by WHO, a WHO panel said in March.

China has shipped millions of its vaccines abroad, and officials and state media have fiercely defended the shots while calling into question the safety and logistics capabilities of other vaccines.

"The global vaccine protection rate test data are both high and low," Gao told state tabloid Global Times on Sunday.

"How to improve the protection rate of vaccines is a problem that requires global scientists to consider," Gao said, adding that mixing vaccines and adjusting immunisation methods are solutions that he had proposed.

Gao also rejected claims by some media reports that he said&nbsp;Chinese&nbsp;COVID-19 vaccines have a low protection rate, telling Global Times that it was "a complete misunderstanding."

China's top disease control official has said the country is formally considering mixing COVID-19 vaccines as a way of further boosting vaccine efficacy. Available data shows Chinese vaccines lag behind others including Pfizer and Moderna in terms of efficacy, but require less stringent temperature controls during storage.

China's top disease control official has said the country is formally considering mixing COVID-19 vaccines as a way of further boosting vaccine efficacy. Available data shows Chinese vaccines lag behind others including Pfizer and Moderna in terms of efficacy, but require less stringent temperature controls during storage. Giving people doses of different vaccines is one way to improve vaccines that "don't have very high rates of protection", Gao Fu, the director of the Chinese Centers for Disease Control and Prevention, said on Saturday, without specifying whether he was referring to foreign or domestic vaccines "Inoculation using vaccines of different technical lines is being considered," Gao told a conference in the Chinese city of Chengdu. Gao said that taking steps to "optimise" the vaccine process including changing the number of doses and the length of time between doses was a "definite" solution to efficacy issues. Two injections of a vaccine developed by China's Sinovac Biotech, when given shorter than three weeks apart, was 49.1 per cent effective based on data from a Phase III trial in Brazil, below the 50 per cent threshold set by World Health Organization, according to a paper published by Brazilian researchers on Sunday ahead of peer review. But data from a small subgroup showed that the efficacy rate increased to 62.3 per cent when the doses were given at intervals of three weeks and longer. The overall efficacy rate for the vaccine was slightly above 50 per cent in the trial. China has developed four domestic vaccines approved for public use and a fifth for smaller-scale emergency use. An official said on Saturday that the country will likely produce 3 billion doses by the end of the year. No detailed efficacy data has been released on vaccines made by China's Sinopharm. It has said two vaccines developed by its units are 79.4 per cent and 72.5 per cent effective respectively, based on interim results. Both vaccine makers have presented data on their COVID-19 vaccines indicating levels of efficacy in line with those required by WHO, a WHO panel said in March. China has shipped millions of its vaccines abroad, and officials and state media have fiercely defended the shots while calling into question the safety and logistics capabilities of other vaccines. "The global vaccine protection rate test data are both high and low," Gao told state tabloid Global Times on Sunday. "How to improve the protection rate of vaccines is a problem that requires global scientists to consider," Gao said, adding that mixing vaccines and adjusting immunisation methods are solutions that he had proposed. Gao also rejected claims by some media reports that he said Chinese COVID-19 vaccines have a low protection rate, telling Global Times that it was "a complete misunderstanding."

China formally considering mixing its COVID-19 vaccines to boost protection rate

The European Union, which buys vaccines on behalf of its 27 member states, has authorized three shots developed in Germany, the U.S. and the U.K.

China aims to create goodwill through vaccine diplomacy

China’s fledgling pharmaceutical industry has at least five vaccines from four producers being tested in more than a dozen countries including Russia, Egypt and Mexico

China prepares large-scale rollout of Covid-19 vaccines

China has put its homegrown COVID-19 vaccines on display for the first time, as the country where the contagion was discovered looks to shape the narrative surrounding the pandemic.

WION Dispatch: China vaccines on display for the first time; Here's the report

Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine

China's CanSino in talks with Russia, Brazil, Chile for Phase III trials of vaccine